Stock Market Reviews

TCRX (TScan Therapeutics, Inc.) News

Get the latest news, insights, and market updates on TCRX (TScan Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• TScan Therapeutics to Participate in Upcoming Investor Conferences
  WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, Se
  Sep 3, 2025 - $TCRX
• TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely
  NasdaqGM:TCRX 1 Year Share Price vs Fair Value Explore TScan Therapeutics's Fair Values from the Community and select...
  Aug 15, 2025 - $TCRX
• TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
  TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025 - $TCRX
• TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) thera
  Aug 12, 2025 - $TCRX
• Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
  Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $TCRX
• Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
  Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $TCRX
• Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
  Twist Bioscience (TWST) delivered earnings and revenue surprises of +12.96% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 4, 2025 - $TCRX
• One TScan Therapeutics Insider Raised Stake By 18% In Previous Year
  From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) during the past 12 months...
  Jul 19, 2025 - $TCRX
• 2 Small-Cap Stocks Under $10 to Buy With Big Potential
  These high-risk, high-reward small-cap biotech stocks deserve a second look.
  Jun 24, 2025 - $TCRX
• TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
  WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time. A webcast of the presentation will be avail
  May 28, 2025 - $TCRX